Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product,…

The Prenylium active ingredient is an extract of the Morus alba tree root, which has been used for centuries in traditional Chinese medicine. Although the plant contains only low quantities of prenylated flavonoids, Clariant's Plant Milking Technology stimulates the production of the total prenylated flavonoids by 2,000 percent. Clariant's product delivers on customer expectations for younger-looking skin by adjusting matrisome components, including glycoproteins, collagen, and proteoglycans. These components are perfectly functional in younger skin; however, an imbalance is noted in matrix components in older people. Prenylium can modulate the CCN1 expression and protect the skin matrisome from degrading.

"Prenylium is developed in a highly sustainable, traceable, and natural environment, thus meeting the consumer demand for environment-friendly ingredients. Its Plant Milking Technology uses an aeroponic system and offers multiple advantages such as no plant destruction during harvest, eco-friendliness, and 100 percent traceability from seed to active ingredient," said Prateeksha Kaul Research Analyst. "Clariant has also proactively developed trend-oriented product lines to meet consumers needs in terms of quality, performance, and reliability."

To ensure the success of the aeroponics method, Clariant performs trials on a small scale for a year. As each plant has different requirements in terms of type and quantity of nutrients, it conducts multiple trials to gauge the best set and quantity of nutrients that will allow higher plant and root growth. In addition, it ensures that the Prenylium active ingredient meets quality expectations and regulatory standards, including Inventory of Existing Cosmetic Ingredients in China (IECIC), ROOT ORIGIN, ISO 16128, and Nagoya Protocol.

"Test results demonstrate the superiority of Prenylium in inhibiting collagenase activity compared to traditional root extracts that show no effect on the collagenase enzyme," noted Kaul. "Its ingredient is unique in terms of performance, concept, and technology, helping the company become a name to reckon with in the sustainable anti-aging active ingredients market."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:

Kristen MooreP: 210.247.3823E: [emailprotected]

About Clariant

Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2019, the company employed a total workforce of 17 223. In the financial year 2019, Clariant recorded sales of CHF 4.399 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant's corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.www.clariant.com

SOURCE Frost & Sullivan

http://www.frost.com

Visit link:
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product,...

REGENCare Life Magazine Interviews NFL’s 3X Super Bowl Champion, Rob Gronkowski, and Atlanta’s Anti-Aging Expert, Dr. Richard Ambrozic, Regarding…

I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal.

ATLANTA (PRWEB) December 14, 2020

Announcing the launch of REGENCare Life Magazine. Published in conjunction with Local Umbrellas C4 Lead Machine, the inaugural issue features interviews with Rob Gronkowski, the Atlanta Braves legendary Ryan Klesko and Atlantas Celebrity Anti-Aging Expert, Dr. Richard Ambrozic (@drrick), regarding the very latest in Regenerative Therapies designed to renew and restore function in the body. The magazines inaugural edition features stories and testimonials from professional athletes and many other patients benefiting from these Allograft Regenerative Therapies.

REGENCare Life Magazine features an interview with Tampa Bay Buccaneers tight end Rob Gronkowski by C. Christie Craig. (See Interview below.)

The highs and lows of football players are well known. When you are young, strong, and focused, the game has no limits. But the body can only take so many hits; there is a huge price to pay for years of playing hard on the field. Rob Gronk Gronkowski, one of the NFLs all-time greatest tight ends, knows this all too well. In 2019, Rob announced his retirement from the New England Patriots, needing a break to focus on his health and well-being. At 30 years old, he had an extraordinary run, making his mark in football history. Fans were devastated and Rob was hurting.

Today, after a multitude of various regenerative treatments throughout last year, Robs new nickname is Mr. Recovery. His body and mind are healed, and he has a fresh new deal with the Tampa Bay Buccaneers. The best part is hes going to share his most amazing discovery. In fact, he is ready to shout it out to all who will listen. Thats good news, because when it comes to overcoming pain, hes someone we should listen to carefully. Not only is he an amazing athlete; he is also a successful businessman and philanthropist.

Gronk was always well-loved by fans and teammates, and many thought his career was over. But he was not the type to give up, and he decided that pain was not going to mean the end of his story. How he eliminated it and got back on the field is an inspiring story for all of us. In this interview, Rob shares how he found his fire and returned to the NFL through regenerative care treatments. Here is the incredible story of his journey back to health and wellness in his own words.

Question: I am here with the greatest tight end in NFL history who now calls himself Mr. Recovery. After a litany of injuries, you are coming out of retirement this year and making your comeback with the Tampa Bay Buccaneers. How did this all happen?

Gronk: Thank you! I am super excited, super pumped up. I feel so good, you know. I let my body heal and recover. Ive been playing football for fifteen plus years, plus along with other sports, and with all this action Ive seen, my body just needed a little rest. I had to investigate and find connections to heal. Dr. Rick turned everything around for me. Its a full-time job as an athlete. Athletes dont just show up. We have to take care of our bodies and find solutions that work. The recovery is cake with Dr. Rick.

Question: Your journey back to health is unprecedented. Few NFL players return to action after retiring like you did. Allografts are the new buzz words for lasting recovery. Is this the type of therapy and injections you received from Dr. Rick at REGENCare?

Gronk: Yes, I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal. This treatment is exactly what I needed. I am sharing this information with others because this treatment isnt only for professional athletes like me. It can help everyone!

Question: How is your healing different with REGENCare Therapy compared to traditional treatment?

Gronk: In your early twenties you really dont get into the treatment. You just do the basics and the bare minimum. But as you get older, you have to treat your body more, you need to find new ways, and thats what Ive been doing over the last few years. Aside from the allografts, there are so many options at REGENCare. Im getting massages, doing vitamin IVs, and lying in the hyperbaric chamber. This chamber fills my body up with clean, pure oxygen. Without oxygen in your body, you are not going to survive! Its just spectacular when you can get more and more oxygen into your system. Your muscle tissues start feeling pliable and loose and it targets all those nagging injuries to help them heal. It is my favorite treatment because I get a nap and I am getting rejuvenated at the same time by all the oxygen. Its great. We also do a couple other treatments to help with recovery, stress management, improving sleep and diet.

Question: Do REGENCare Therapy treatments make a difference in how fast you recover and heal?

Gronk: I definitely feel a big difference. Back in the day, I would just let my body heal naturally, and when I say naturally, I would just do the bare minimum. I would be running around on it. I would be partying on the injury while it was trying to heal. But I was so young then, and I could get away with it. But now that I want to continue my career, and Im older, I learned that I needed to start adapting. You got to adapt to the change, you got to start adapting to your body. And you know, finding that adaptation includes a whole spectrum of healing treatments from allografts and finally, to proper nutrition.

Question: How does your focused mindset play a role in your healing? Is it an importantpart of your treatment process?

Gronk: Yeah, definitely! Some people can be telling you to do this, and you just got to stick with your gut. You got to stick with your heart, knowing what is best for your body. To know that, you have to go through a lot of experiences. Ive tried many, many things, and some do work for me. I focus on all the natural treatments that you could do for yourself. I find the best ones that suit me and enjoy em while doing em.

What would you tell your friends and teammates who are suffering from chronic pain and injuries about these regenerative treatments?

Gronk: Just get started on it now! The longer you wait, the harder it is going to be to heal that injury and nagging pain. The longer you wait, it gets more settled into your brain that you have that nagging pain. So hop on it ASAP, get moving, get cruising on it, find some good workouts, strengthen your core tight, and start small. Thats where it begins. You dont got to go big at all. Just start small and make little changes.

Question: So whats next for you? You have an exciting season with Tampa Bay, what are some of the things that youre doing to prepare?

Gronk: You know, Im just hanging out! Throwing footballs, doing football workouts, doing band workouts, doing some strength workouts, just doing it all at high speed. Its a lot of expectations for sure. Just have to go in and be a consistent player and youre just ready to go. Im just excited to get back out into the field and play some football and help out the team.

Question: If you were to leave a legacy behind, what would it be?

Gronk: Just working hard, being the best teammate that I can be and doing the best that I can to help out the team. Now that Dr. Rick has helped me to recover, I can achieve this and more.

Get your copy & learn more about how Allograft Regenerative Therapies can help you at https://www.REGENCare.life.

Regenerative Medicine Treatments at REGENCare

Our regenerative medicine treatments utilize regenerative medicine to encourage tissue healing throughout affected areas. REGENCare utilizes regenerative medicine allografts, Pulsed Electro-Magnetic Field technology to stimulate and exercise the cells and address cellular dysfunction and support overall wellness, Shockwave Therapy to promote regeneration and repair of the bones, tendons and other soft tissues, Georgias first PRISM Light Pod which uses specific wavelengths of light that pass through layers of skin and interact within the body to stimulate regrowth and repair, IV Hydration which provides the vitamins, minerals, and amino acids your body needs, Hyperbaric Oxygen Therapy which can significantly increase the concentration of circulating progenitor cells within the peripheral circulation system, and more. We may be able to help in orthopedic conditions, like osteoarthritis, meniscus and cartilage tears, tendinitis, joints and back pain, inflammation, hair restoration, skin rejuvenation and anti-aging treatments.

About Richard Ambrozic, MD, Founder and CEO, REGENCare:

Dr. Ambrozic (@drrick) earned his MD from the University of Alberta. He completed a residency in health prevention and family medicine at the University of British Columbia and has completed an anti-aging fellowship from the University of South Florida. The American College of Sports Medicine, American Academy of Anti-Aging Medicine, American Medical Association, Medical Association of Georgia, and the American Society for Laser Medicine and Surgery. He is a member of the Harvard Medical School Postgraduate Association. He is an expert in Allografts, Lasers, and Anti-Aging.

Dr. Ambrozic is the founder of REGENCare, with locations in Buckhead, Atlanta, Jupiter/Palm Beach Florida, and soon around the world. He treats professional athletes, celebrities, and patients from all walks of life interested in regenerative and anti-aging medicine. Healing the body naturally and safely, without pills and unnecessary surgery is most important. Dr. Ambrozic has traveled the world to bring the very latest and state-of-the-art regenerative medicine protocols, technology, and procedures to his clinics.

Please call our office to book your free consultation so Dr. Ambrozic and the REGENCare team can plot your course to better health.

Call 678-430-3039 or email at appointment@regencare.life.

Please visit our website at https://www.REGENCare.life

Please visit our Social Media:

https://www.instagram.com/drrick/https://www.facebook.com/richard.ambrozichttps://www.linkedin.com/in/dr-richard-ambrozic-70206124/

Contact:

REGENCareDr. Richard Ambrozic (@drrick)Office Phone: 678-430-3039 Email: appointment@regencare.lifeAddress: 240 Pharr Rd. Atlanta, GA 30305 (Buckhead Village)

Follow this link:
REGENCare Life Magazine Interviews NFL's 3X Super Bowl Champion, Rob Gronkowski, and Atlanta's Anti-Aging Expert, Dr. Richard Ambrozic, Regarding...

Global Medical Aesthetics Market 2020- Industry Analysis Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 – The…

Databridgemarketresearch.com Present Global Medical Aesthetics Market Industry Trends and Forecast to 2027 new report to its research database. This research report understands the current and future of the market in both developed and emerging markets. The Global Medical Aesthetics Market report assists in realigning the business strategies by highlighting the business priorities. It throws light on the segment expected to dominate the industry and market. It forecast the regions expected to witness the fastest growth. This report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and Segments.

This Global Medical Aesthetics Market tracks the major market events including product launches, development trends, mergers, acquisition and the innovative business strategies opted by key market players. The Global Medical Aesthetics Market report also focuses on industry-specific drivers, restraints, opportunities and challenges in the market. The global market is bifurcated into sub-segments that can provide classified data regarding the latest trends in the market.

Global Medical Aesthetics Market By Product type (Aesthetic Lasers, Energy Devices, Body Contouring Devices, Facial Aesthetic Devices, Aesthetic Implants, Skin Aesthetic Devices), Application (Anti-Aging and Wrinkles, Facial and Skin Rejuvenation, Breast Enhancement, Body Shaping and Cellulite, Tattoo Removal, Vascular Lesions, Psoriasis and Vitiligo, Others), End User (Cosmetic Centres, Dermatology Clinics, Hospitals, Medical Spas and Beauty Centres), Distribution Channel (Direct Tender, Retail), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global medical aesthetics market is projected to register a healthy CAGR of 12.1% in the forecast period of 2019 to 2026.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-medical-aesthetics-market

Competitive Analysis: Global Medical Aesthetics Market

Some of the major players operating in the global medical aesthetics market are Allergan, Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd., Cynosure, Syneron Medical Ltd, Aerolase Corp., A.R.C. Laser Gmbh, Asclepion Laser Technologies Gmbh, Btl, Cutera, Eclipse, Lutronic, Mentor Worldwide Llc, Merz Pharma, Quanta System, Sciton Inc., Sharplight Technologies Inc, Syneron Medical Ltd., Venus Concept.

Aesthetics devices are an innovative advancement, providing a solution to patients which deal with the ingenuity of creating beauty. The medical aesthetics devices is a growing market owing to its benefits such as maintaining the youthful appearance, pain free and non-invasive beauty treatments, maintenance free skin that remains smooth and hairless without the need for shaving, waxing or unpleasant hair treatments, improving the cosmetic appearance, and technological advancement in medical aesthetics devices.

The market is showing a substantial growth in the emerging countries as these countries are adapting to the trends of urbanization. Brazil, South Africa, Thailand and many others have improved in the past one decade. People are opting different aesthetics surgeries to maintain themselves, which give them better results without any stressful physical efforts. Medical Aesthetics is one of the most trending concepts of the 21stCentury which will show a substantial increase in the future as there is a great technological advancement and innovation in the field by the companies dealing with these devices making them safer and even less invasive leading to more population opting for these procedures.

Segmentation: Global Medical Aesthetics Market

Global medical aesthetics market is segmented into 4 notable segments such as product type, type of care, accessories and end user

Grab Your Report at an Impressive 30% Discount! Please click Here@https://www.databridgemarketresearch.com/request-a-discount/global-medical-aesthetics-market

Product Launch:

Allergan

The company was founded in 2013 and headquartered at Dublin, Ireland. The company is focused on developing, manufacturing and commercializing branded device, biologic, pharmaceutical, surgical and regenerative medicine products for patients throughout the world. The main business segments are US Specialized Therapeutics, US General Medicine, International. The revenue of the company in healthcare sector 2018 was USD 16,550.8 Million. The company has global presence in North America, Asia Pacific, South America, Europe and Middle East & Africa.

Access Full Report athttps://databridgemarketresearch.com/reports/global-medical-aesthetics-market/

Bausch Health Companies Inc.

The company was founded in 1959 and headquartered at Quebec, Canada. The company is engaged in manufacturing and marketing a broad range of branded and generic pharmaceuticals, over-the-counter (OTC) products and medical devices. The main business segments are Bausch + Lomb/International, Branded Rx, U.S. Diversified Products. The revenue of the company in healthcare sector 2018 was USD 8,174.8 Million. The company has global presence in North America, Europe, the Middle East, Africa, Asia Pacific and Latin America.

Luimenis

The company was founded in 1991; headquarter in Yokeneam, Israel. The company is engaged in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). The company has global presence in North America, South America, Europe, Asia, Africa and Australia.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Medical Aesthetics Market 2020- Industry Analysis Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 - The...

Should education be a part of human engineering? – Sunday Observer

With genetic engineering, well be able to increase the complexity of our DNA and improve the human race. But itll be a slow process, because one will have to wait about 18 years to see the effect of changes to the genetic code. Stephen Hawking

Modern eugenics, better known in the present world as human genetic engineering has become one of the most important research areas, since genetic engineering can prevent and/or cure diseases or improve the human body in significant ways.

Even though potential health benefits of human gene therapy are enormous one should not overlook the equally staggering potential dangers it also brings.

Genetic testing already allows parents to identify some diseases in their child in utero which will give them the choice to decide whether they want to terminate the pregnancy.

Genetic testing

This can be extended to detect negative traits implicated by a particular gene and try to eliminate it or modify it. This becomes controversial since what exactly constitutes negative traits is open to interpretation. Many people think the laws of nature should not be tampered with, even if the intentions of doing so are backed by the purest of motives.

Advancements in genetic engineering and modern research in the area of eugenics these days do not get as much publicity as the new findings and applications in the area of ICT and Artificial Intelligence (AI).

As in any other area of science and technology, genetic engineering also has its good and bad coming with it leaving the choice of using it for selfish reasons or for the betterment of the world in general, in the hands of human beings.

This is where the question: Should education be a part of human engineering? comes to the surface since it is obvious that the advancement of technology comes through science and technology education.

But, if the system of education in which science and technology education of the kind is facilitated does not emphasise the importance and provide opportunities to develop ones ethical and moral standards then the development of such technologies can, in the long run, do more harm than good.

The practice or the concept of improving the human species by selectively mating people with specific desirable hereditary traits is known as Eugenics. It supposedly aims to reduce human suffering by breeding out diseases, disabilities and so-called undesirable characteristics from the human population. The word eugenics is supposed to have been coined by Sir Francis Galton in the late 1800s to mean well-born or good creation using the Greek words eu meaning good and genos meaning birth.

Eugenics

Even though Galton gets the credit for introducing the concept and the word eugenics in modern history, Platos The Republic mentions about creating a superior society by procreating high-class people together and discouraging reproduction among the lower classes and/or cross breeding.

Historically, eugenics encouraged people of so called superior class to reproduce more and discouraged reproduction of the mentally challenged or anyone who fell outside the social norm.

Even though eugenics got all its negative publicity due to Adolf Hitlers obsessive attempts to create a superior Aryan race during the years leading to World War II, he has mentioned in his books that he has followed American eugenics very closely in the 1930s.

In 1896, the state of Connecticut, in the USA, made it illegal for people with epilepsy or who were feeble-minded to marry.

As the concept of eugenics was becoming popular, in the early 1900s, scientists and administrators in the USA established a eugenics record office to track families and their genetic traits.

There have been over 20,000 forced sterilisations in state mental institutions in the state of California under the guise of protecting the society from the offspring of people with mental illness.

Thirty-three states eventually allowed involuntary sterilisation of anyone who deemed unworthy to procreate according to the definitions of the lawmakers at the time. Records show that close to 50 percent of Native Americans were sterilised between 1970 and 1976.

Some of the women have been sterilised during other surgical procedures without their knowledge. Such occurrences were taking place in the USA long after Hitlers trials of creating the Aryan race.

Genetic differences

Even if we do not use the word eugenics, as long as we do the same thing with the expectation of similar results, the consequences would be the same.

There may be genetically enhanced athletes performing in Olympics and in professional sports in the future. It may seem unfair just as the usage of steroids or other enhancement drugs is considered to be.

But, the supporters of human engineering might argue that it has always been the case where some humans are born with better performance abilities than others and the ability to manipulate the genes is also a part of the natural progress of human knowledge. In fairness, enhanced genetic differences would be no worse than natural ones, assuming that they were safe and made available to anyone interested in doing so.

In a world dominated by competition from kindergarten to universities and beyond, parents would be lined up to receive the services of genetic engineers to give their children every possible advantage.

The advancement of science and technology, though it can bring much good, it is dangerous since it is used by humans themselves who have not shown any development in their ethical and moral behaviour.

If the word spiritual can be used to denote any or all activities which can drive the human being forward towards a higher state of consciousness, then an essential part of an education system would be a support system for the participants to improve their spirituality.

This type of spirituality has nothing to do with religion but will be capable of guiding the thought process of the human being away from using his knowledge against the common good.

The writer has served in the higher education sector as an academic for over twenty years in the USA and thirteen years in Sri Lanka and can be contacted at [emailprotected]

Originally posted here:
Should education be a part of human engineering? - Sunday Observer

Explained: What US FDA nod for genetically modified pigs means – The Indian Express

By: Explained Desk | New Delhi | Updated: December 19, 2020 12:45:50 pmThis undated photo provided by Revivicor, Inc., a unit of United Therapeutics, shows a genetically modified pig. (Revivicor, Inc. via AP)

This week, the US Food and Drug Administration (FDA) approved a first-of-its-kind intentional genomic alteration (IGA) in a line of domestic pigs referred to as GalSafe pigs. These pigs may be used for food and human therapeutics, the FDA has said. This will be the first time that the regulator has approved an animal biotechnology product for both food and biomedical purposes.

What is intentional genomic alteration?

Intentional genomic alteration in animals means making specific changes to the genome of the organism using modern molecular technologies that are popularly referred to as genome editing or genetic engineering. However, there are other technologies that can be used to make IGAs in animals.

Such changes in the DNA sequence of an animal may be carried out for research purposes, to produce healthier meat for human consumption and to study disease resistance in animals among other reasons. One example is of using IGAs to make an animal more susceptible to certain diseases such as cancer, which helps researchers get a better understanding of the disease and develop new therapies to treat it.

The FDA maintains that the only difference between an animal with an IGA and one that does not have an IGA is that the IGA gives them a new trait or characteristic, such as faster growth or resistance to certain diseases.

Essentially, an IGA is inserted into an animal to change or alter its structure and function and the FDA makes sure that the IGA contained in the animal is safe for the animal and safe for anyone who consumes a product or food derived from the animal. Follow Express Explained on Telegram

What does FDAs recent approval mean?

The FDA made the announcement this week and allowed IGA in GalSafe pigs to eliminate a type of sugar found in mammals called alpha-gal. This sugar is present on the surface of these pigs cells and when they are used for products such as medicines or food (the sugar is found in red meats such as beef, pork and lamb), the sugar makes some people with Alpha-gal Syndrome (AGS) more susceptible to developing mild to severe allergic reactions.

Since GalSafe pigs may potentially be used to produce human medical products, IGA will help eventually free these products from detectable alpha-gal sugar, thereby protecting their human consumers from potential allergies.

According to the FDA, GalSafe pigs may be used to make the blood-thinning drug heparin.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read more:
Explained: What US FDA nod for genetically modified pigs means - The Indian Express

A closer look at the genomes of microbial communities in the human mouth – Tech Explorist

Some bacteria are abundant in specific locations while absent from others. But, how did the bacteria get into the wrong place? How do we add the good bacteria into the right place when the biogeography has gotten out of whack?

Bacterias are so tiny and small that it is difficult to characterize which subgroups of bacteria live and what genes or metabolic abilities allow them to thrive in these wrong places.

Scientists from Harvard University studied the human oral microbiome and discovered impressive variability in bacterial subpopulations living in some mouth regions.

Co-author A. Murat Eren, assistant professor in the Department of Medicine at the University of Chicago, said, The mouth is the perfect place to study microbial communities. Not only is it the beginning of the GI tract, but its also a very unique and small environment thats microbially diverse enough that we can start to answer interesting questions about microbiomes and their evolution.

The mouth contains a surprising amount of site-specific microbes in different areas. For instance, the microbes found on the tongue are very different from the microbes found on the teeth plaque. Your tongue microbes are more similar to those living on someone elses tongue than they are to those living in your throat or on your gums!

Scientists scoured through public databases and downloaded 100 genomes that represented four bacteria species commonly found in the mouth, Haemophilus parainfluenzae, and the three oral species of the genus Rothia. Using these bacterias as references, scientists tend to discover their relatives sampled in hundreds of volunteers mouths from the Human Microbiome Project (HMP).

Lead author Daniel R. Utter said,We used these genomes as a starting point, but quickly moved beyond them to probe the total genetic variation among the trillions of bacterial cells living in our mouths. Because thats what were curious about, not the arbitrary few that have been sequenced.

Using the approach called metagenomics, scientists deeply examined the genomes of the microbes, which led to a shocking discovery. They found a tremendous amount of variability. What was more surprising was the patterning of that variability across the different parts of the mouth, specifically, between the tongue, cheek, and tooth surfaces.

For example, within a single microbe species, the researchers found distinct genetic forms strongly associated with a single, different site within the mouth. In many cases, the team was able to identify a handful of genes that might explain a particular bacterial groups specific habitat. Applying metagenomics, the scientists were also able to identify specific ways free-living bacteria in peoples mouths differed from their lab-grown relatives.

Colleen Cavanaugh from the Department of Organismic and Evolutionary Biology, Harvard University, said,Having identified some strong bacterial candidates that could determine adaptation to a particular habitat, we would like to test these hypotheses experimentally. These findings could potentially be the key to unlocking targeted probiotics, where scientists could use whats been learned about each microbes habitats requirements to engineering beneficial microbes to land in a specified habitat.

Co-author Jessica Mark Welch, an associate scientist at the Marine Biological Laboratory, said,The mouth is so easily accessible that people have been working on bacteria from the mouth for a long time.

Every environment we look at has these complicated, complex communities of bacteria, but why is that? Understanding why these communities are so complex and how the different bacteria interact will help us better understand how to fix a bacterial community thats damaging our health, telling us which microbes need to be removed or added back in.

Utter said,This study and others like it can provide new insights on the role of oral microbes in human health. The ability to identify specific genes behind habitat adaptation has been somewhat of a holy grail in microbial ecology. We are very excited about our contributions in this area!

View original post here:
A closer look at the genomes of microbial communities in the human mouth - Tech Explorist

Genetic mutation increases one’s susceptibility to mesothelioma – UH System Current News

Postdoctoral research fellow and collaborator Angela Bononi in Carbones lab.

New research has found that individuals born with inherited mutations of the BLM gene are more susceptible to developing mesothelioma, especially upon exposure to asbestos. The study was conducted by University of Hawaii Cancer Center researcher Michele Carbone and collaborators, and was published in the Proceedings of the National Academy of Sciences.

Individuals who inherit two mutated copies of the BLM gene are affected by the rare Bloom Syndrome, characterized by short stature, a red rash over the nose and cheeks, mild immune deficiency and an increased susceptibility to develop various cancers. However, approximately one in every 900 individuals is born with only one inherited mutation of the BLM gene. The cells of these individuals produce only half of the normal amount of BLM protein, which was suspected, and has now been proven, to increase their risk of developing cancer.

Carbones previous discovery of the BAP1 mutation, which signifies an increased susceptibility to cancer, led to the investigation of other genetic mutations with similar functionsincluding those of the BLM gene. This resulted in the establishment of a specific clinical trial at the National Cancer Institute in Bethesda, Maryland, that addresses the potential future healthcare needs of carriers of germline mutations, who have a high risk of developing mesothelioma. In this trial, individuals born with genetic mutations are followed for prevention, early detection and personalized therapy when they develop cancer.

To further this research, the National Institutes of Health has awarded Carbone a grant to study a population in northern Nevada, a population at risk of exposure to asbestos and to other harmful mineral fibers and carcinogens present in the natural environment.

The project is in collaboration with Haining Yang of the UH Cancer Center, and Joe Grzymski of the Desert Research Institute. The studys goal is to identify carriers of genetic mutations who may be more susceptible to developing cancer when exposed to these carcinogens. The investigators have already found that 80 out of the 28,553 northern Nevada residents have inherited these BLM mutations, and should benefit greatly from prevention and early detection approaches.

See the article here:

Genetic mutation increases one's susceptibility to mesothelioma - UH System Current News

Making Cents of Mesothelioma – Curetoday.com

Finances can become the deciding factor in which treatment a patient with cancer chooses to receive, where they receive it and if they can keep on that treatment regimen for an extended period of time.

Its crucial for all patients to find the right treatment team and that may mean traveling further from home for days or even weeks. For patients with mesothelioma, being treated at a large academic cancer center is key since this disease is rarer than other cancer types.

Certain organizations across the country have financial assistance programs to help. For instance, CancerCare, the leading national organization providing free, professional support services and information to those affected by cancer, has a new program that exclusively offers assistance to patients with mesothelioma.

Once a patient is interviewed by phone and completes a financial application, they are eligible to receive a portion of grant money from the Mesothelioma Transportation Assistance Program that can be used for services such as air travel to a treatment facility, lodging and airfare.

Francine Shuman is thankful she qualified for this help as she has to travel from Augusta, Georgia, to Atlanta, to receive treatment at Winship Cancer Institute of Emory University, which requires driving two hours one way from her home to the cancer center, as well as staying overnight a few days in a hotel. Ive got bills to pay. I cant afford it, she says.

Shuman received a peritoneal mesothelioma diagnosis in February 2020 and after undergoing chemotherapy, she recently had surgery to remove the cancer that develops in the lining of the abdomen. She believes her cancer was caused by years of inhaling talcum powder that she used on her three daughters as babies. Talc is a mineral that can absorb moisture and because its found in close proximity to asbestos a known carcinogen in the earth, there is concern that talc can become contaminated.

After calling several organizations, Shuman finally connected with CancerCare and through the program, Shuman received a $1,000 grant for expenses. I was told I would get the loan and I wouldnt have to pay it back. And I just thanked the Lord because I didnt know how I was going to get back and forth, she says.

To initiate the process for the Mesothelioma Transportation Assistance Program, the person who received the diagnosis or a caregiver can call CancerCares HOPEline at 1-800-813-4673 or email Charlotte Ference, a social worker, at cference@cancercare.org.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Follow this link:

Making Cents of Mesothelioma - Curetoday.com

Study Confirms Benefits of Extended Pleurectomy Decortication for Patients with Mesothelioma – Mesothelioma.net Blog

Published on December 16, 2020

Though malignant pleural mesothelioma remains one of the most challenging types of cancer to treat, physicians continue to refine surgical approaches and improve patient outcomes. A recently conducted retrospective study has confirmed the benefits of extended pleurectomy decortication as a surgical approach in the treatment of the rare, asbestos-related disease, indicating that patients who opt for this approach have a low risk of postoperative mortality. The study confirms that the surgery leads to prolonged overall survival when successful removal of all cancerous tissue is achieved.

The study was published in theAnnals of Surgeryand was a retrospective chart review of the records of 355 consecutive patients with malignant pleural mesothelioma. The patients had all been treated at a single facility between 2007 and 2015. All underwent thoracotomy for planned pleurectomy decortication and were evaluated for both short and long-term outcomes, as well as associated prognostic factors.

Pleurectomy decortication is a lung-sparing surgery that removes the pleura and visible tumor masses, while the extended version of the surgery also removes the pericardium and part of the diaphragm. Both procedures are considered less invasive than extrapleural pneumonectomy, a mesothelioma surgery that removes all of these organs as well as the lung. In all cases the surgery is recommended to be used in combination with systemic approaches to address metastatic disease and optimize outcomes.

The results of the study were encouraging for mesothelioma patients opting for the lung-sparing surgery. Most patients experienced only low-grade complications, with a thirty-day mortality of 3% and a 90-day mortality of 4.6%. The most striking difference in overall survival existed between those for whom the surgery successfully removed all malignant tissue, with a median overall survival of 23.2 months, while for those whose surgery did not remove all malignancies the overall median survival was just 11.6 months. Other factors shown to negatively impact survival were male vs female and higher tumor stage, while use of chemotherapy, intraoperative heated chemotherapy and epithelioid histology were shown to positively impact survival.

If you have been diagnosed with malignant mesothelioma and need more information on treatment options and other resources, the Patient Advocates at Mesothelioma.net can help. Contact us today at 1-800-692-8608.

Learn more about and contact Terri

Continue reading here:

Study Confirms Benefits of Extended Pleurectomy Decortication for Patients with Mesothelioma - Mesothelioma.net Blog

Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma – OncLive

Checkpoint inhibitors have failed to improve progression-free survival (PFS) and overall survival (OS) as second-line therapy and maintenance therapy in small cell lung cancer (SCLC), but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

The frontline role with immunotherapy has extended to patients with mesothelioma, as well.

SCLC and mesothelioma have been difficult cancers to treat, and immunotherapy has not made an impact until very recently, where, in the first-line setting, we have improved outcomes and new standards of care for the treatment of SCLC and mesothelioma, said Naiyer A. Rizvi, MD, Price Family Professor of Medicine, director of Thoracic Oncology, and co-director of Cancer Immunotherapy at Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, said in a presentation during the 5thAnnualInternational Congress on Immunotherapies in Cancer.

The first robust trial that demonstrated the potential for immunotherapy up front was the phase 3 IMpower133 trial. In the trial, patients with extensive-stage SCLC were randomized 1:1 to 1200 mg of intravenous atezolizumab (Tecentriq) plus carboplatin or etoposide for four 21-day cycles, or placebo plus carboplatin or etoposide followed by maintenance atezolizumab and placebo, respectively.

At a median follow-up of 13.9 months, the median PFS was 5.2 months in the atezolizumab arm vs 4.3 months in the placebo arm (HR, 0.77; 95% CI, 0.62-0.96; P = .017).1 The 6-month PFS rate was 30.9% in the atezolizumab arm vs 22.4% in the placebo arm. The 12-month PFS rates were 12.6% and 5.4%, respectively.

At a median follow-up of 22.9 months, the median OS was 12.3 months with atezolizumab vs 10.3 months with placebo (HR, 0.76; 95% CI, 0.60-0.95; P = .0154).2 The 18-month OS rates were 34.0% and 21.0%, respectively. The 24-month OS rates were 22.0% and 16.8%, respectively.

The median duration of response (DOR) was 4.2 months in the atezolizumab arm vs 3.9 months in the placebo arm (HR, 0.70; 95% CI, 0.53-0.92). However, more than half of patients in the placebo arm experienced ongoing response in the atezolizumab arm at last follow-up (n = 7 vs n = 18, respectively).

In the subgroup analysis, all patients except those with brain metastases (HR, 1.07; 95% CI, 0.47-2.43) derived benefit from atezolizumab.

IMpower133 is really the first study in over 20 years to really show a meaningful improvement in OS vs standard of care in first-line SCLC. These data led to the adoption of chemotherapy plus immunotherapy as a first-line standard of care for extensive-stage SCLC, said Rizvi.

These data were recapitulated in findings from the phase 3 CASPIAN trial, said Rizvi. In the trial, patients with extensive-stage SCLC were randomized 1:1:1 to 1500 mg of durvalumab (Imfinzi) plus etoposide every 3 weeks for up to 4 cycles, etoposide every 3 weeks for up to 6 cycles, or durvalumab plus 75 mg of tremelimumab plus etoposide for up to 4 cycles, followed by durvalumab, optional prophylactic irradiation, and durvalumab, respectively.

At over 2 years of follow-up, the median OS was 12.9 months in the durvalumab/etoposide arm vs 10.5 months in the etoposide arm (HR, 0.75; 95% CI, 0.62-0.91; P = .0032). The 24-month OS rates were 22.2% and 14.4% respectively.3

The median PFS was 5.1 months in the durvalumab/etoposide arm vs 5.4 months in the etoposide arm (HR, 0.80; 95% CI, 0.66-0.96). The 24-month PFS rates were 11.0% and 2.9%, respectively.

The trial was not powered to compare durvalumab plus chemotherapy vs durvalumab plus tremelimumab plus chemotherapy, but these 2 arms did perform fairly similarly, and both did perform similarly to chemotherapy alone, said Rizvi.

In an exploratory analysis, tumor mutational burden was not shown to be predictive of an improvement in OS for durvalumab plus or minus tremelimumab/etoposide vs etoposide alone, indicating that the marker should not be used to select patients for treatment.4

Despite the progress that has been made, there is room for improvement, said Rizvi, who cited the phase 3 SKYSCRAPER-02 trials as 1 study that could push the needle further.

In SKYSCRAPER-02, patients will be randomized to 1:1 to 1200 mg of atezolizumab plus chemotherapy plus 600 mg of tiragolumab every 3 weeks for 4 cycles or atezolizumab plus placebo in the same schedule, followed by atezolizumab/tiragolumab or atezolizumab/placebo, respectively.

Immunotherapy has also been subject to research in mesothelioma, explained Rizvi, who pointed to the phase 3 CheckMate 743 trial, where patients with malignant pleural mesothelioma will be randomized 1:1 to 3 mg/kg of nivolumab (Opdivo) every 2 weeks plus 1 mg/kg of ipilimumab (Yervoy) every 6 weeks or cisplatin or carboplatin plus pemetrexed for 6 cycles.

Initial results from CheckMate 743 demonstrated a median PFS of 6.8 months with chemotherapy vs 7.2 months with chemotherapy (HR, 1.00; 95% CI, 0.82-1.21). The 24-month PFS rates were 16% and 7%, respectively.5

OS data, when broken down by subtype, revealed a significant improvement with the combination vs chemotherapy in patients with non-epithelioid tumors, at 18.1 months vs 8.8 months, respectively (HR, 0.46; 95% CI, 0.31-0.68). The 24-month OS rates were 38% and 8%, respectively.

In epithelioid tumors, the median OS was 18.7 months with the combination vs 16.5 months with chemotherapy (HR, 0.86; 95% CI, 0.69-1.08). The 24-month OS rates were 42% and 33%, respectively.

These data are really meaningful, supporting immunotherapy only as first-line therapy [in mesothelioma], said Rizvi.

Additionally, although OS favored the combination vs chemotherapy, irrespective of PD-L1 expression, patients who had greater than 1% expression derived more benefit from the combination (HR, 0.69) vs those with PD-L1 expression less than 1% (HR, 0.94).

The response rates were comparable in the combination and chemotherapy-alone arm, at 40% and 43%, respectively. The median DOR was 11.0 months and 6.7 months, respectively. At 2 years, 32% of patients in the combination arm were still in response vs 8% in the chemotherapy-alone arm.

Link:

Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma - OncLive

Researcher Delivers Promising News on Immunotherapy Role in Mesothelioma – Mesothelioma.net Blog

Published on December 15, 2020

Immunotherapy represents real hope in the fight against malignant mesothelioma, as well as in other types of cancer. A presentation delivered at the 5thAnnual International Congress on Immunotherapies in Cancer reinforced the sense of optimism, as a top researcher indicated improvements in the results being seen.

Though much of the focus on the use of immunotherapy in malignant mesothelioma has been on its application as a second-line or maintenance therapy after initial treatment with chemotherapy, the latest research is pointing to its role as a frontline protocol. According to Naiyer A. Rizvi, MD, Price Family Professor of Medicine, director of Thoracic Oncology, and co-director of Cancer Immunotherapy at Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, immunotherapy agents are increasingly yielding better results as an initial application.

SCLC and mesothelioma have been difficult cancers to treat, and immunotherapy has not made an impact until very recently, where, in the first-line setting, we have improved outcomes and new standards of care for the treatment of SCLC and mesothelioma, he told a gathering of researchers.

Dr. Rizvi detailed the use of immunotherapy in the phase 3 CheckMate 743 trial, where patients with malignant pleural mesothelioma are being randomized between doses of Opdivo and Yervoy or the more traditional cisplatin or carboplatin plus pemetrexed treatment. He explained that thus far, the progression free survival rates and the overall survival rates both demonstrate significant improvement with the immunotherapy combination when used in patients with non-epithelioid tumors, and less dramatic results in those with epithelioid tumors. These data are really meaningful, supporting immunotherapy only as first-line therapy [in mesothelioma], said Rizvi.

As researchers continue exploring innovative treatments for malignant mesothelioma, having access to up-to-date information becomes more important than ever. For access to the resources you need, contact the Patient Advocates at Mesothelioma.net today at 1-800-692-8608.

Learn more about and contact Terri

Go here to read the rest:

Researcher Delivers Promising News on Immunotherapy Role in Mesothelioma - Mesothelioma.net Blog

Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR – T cell Therapy with the FDA – BioSpace

Dec. 17, 2020 17:45 UTC

HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma (the Company) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the submission of two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) for the initiation of:

--- Phase 1 clinical trial of an intravenously (IV) administered allogenic CAR-T for epithelial ovarian carcinoma (EOC) and malignant pleural mesothelioma (MPM) and

--- Phase 1 clinical trial of an intrapleural/intraperitoneal (IP) administered allogenic CAR-T for EOC and MPM.

Kiromics proprietary PD1 Gamma-delta CAR (PD1-GDT CAR) T cell therapy is a novel method for off-the-shelf allogeneic CAR T cells derived from healthy donors. We believe our proprietary gamma-delta T cell manufacturing and distribution will offer significant advantages over competitive manufacturing technologies.

The initial dose escalation component of each CAR-T trial is projected to enroll approximately 12 patients over 4 months at two sites.

The first in-human dosing is targeted for 1Q-2021.

"It's an exciting time to see our technology go into the clinic. This is the culmination of +25 years of research and development which has spanned the globe with international contributions and scientific collaborations from the sharpest minds of our time. Our gamma-delta T-cells are designed to offer clinicians a treatment option with:

-- higher efficacy,

-- higher safety (reducing graft vs. host risks), and

-- lower manufacturing and distribution costs vs. cellular therapy technologies of the past," says Dr. Maurizio Chiriva-Internati, PhD, CEO of Kiromic.

"This first in-human off-the-shelf allogenic gamma-delta chPD1 CAR-T cell therapy trial will mark a major milestone, not only for Kiromic, but also for clinicians who have been frustrated with the lack of CAR T cell treatment options for solid malignancies, since current CAR T cell therapies are only approved for hematologic malignancies, with all of the drawbacks of autologous based platforms, commented Dr. Scott Dahlbeck, MD, Chief Medical Officer of Kiromic.

"The cGMP suite consists of 5 clean rooms which will be used to manufacture the Companys off-the-shelf allogeneic therapies during clinical trials. The Company is fully ready for this IND filing and has the clinical manufacturing capability to supply its clinical trials," commented Mr. Tony Tontat, CFO, COO of Kiromic.

"Kiromics proprietary PD1 Gamma-delta CAR (PD1-GDT CAR) T cell therapy is a novel method for off-the-shelf allogeneic CART T Cells derived from healthy donors. As we continue to grow our targets and our clinical programs, our IP portfolio is continually being fortified in all major geographies, and we look forward to updating our investors in upcoming presentations and filings," commented Mr. Gianluca Rotino, Chief of Strategy and Innovations of Kiromic.

About Epithelial Ovarian Carcinoma

Ovarian tumors grow rapidly and metastasize early with a very aggressive disease course, either through direct extension from the ovarian/fallopian tumor to neighboring organs (bladder/colon), or by detaching from the primary tumor, and then spreading and adhering to intraperitoneal organs.

Epithelial ovarian carcinoma represents the vast majority of ovarian cancers and the most common histologic subtype is high grade serous epithelial ovarian carcinoma. Unlike most other cancers, ovarian carcinoma rarely disseminates through the vasculature, although pelvic and/or para-aortic lymph nodes can be involved. When ovarian cancer spreads to the mesothelium of the organs within the peritoneal cavity, it can result in encasement of these organs with significant pain and eventual obstruction of the stomach, large, and small intestines.

Despite advances in surgical techniques and intensive combination chemotherapy approaches, the survival rate substantially decreases after ovarian cancer has metastasized to pelvic organs (such as the uterus, fallopian tubes, bladder, and rectum), metastasized across the pelvic cavity to the abdominal organs and tissue (such as the omentum, small intestine, and retroperitoneal lymph nodes), or metastasized beyond the peritoneal cavity to distant parenchymal organs such as the liver and lung.

The ovarian cancer tumor microenvironment (TME) within the peritoneal cavity is a key element in the support of ovarian cancer growth, and only by addressing the TME, along with the ovarian cancer tumor cell itself, will significant advances be achieved.

Since ovarian cancer 5 year survival statistics have improved only slightly over the last few decades, innovative approaches such as Kiromics administration of a PD1-GDT CAR, which is designed to address the TME of EOC, are desperately needed.

About Malignant Pleural Mesothelioma

Patients with a diagnosis of mesothelioma are generally considered to be incurable, and typically present late, with multiple signs and symptoms such as shortness of breath, chest pain, cough, hemoptysis, dysphagia, weight loss, fatigue, night sweats, and face/arm swelling which often precludes surgical options. Chemotherapy and radiation therapy are also options but are often only palliative, with or without an attempted surgical resection.

If the patient is one of the few considered to be a surgical candidate, the surgical objective will be to obtain a maximal cellular reduction (MCR), followed by chemotherapy +/- radiation therapy. Yet even with an MCR and adjuvant therapies, the vast majority of patients still experience a recurrence, most of which are local, and when the tumors do recur, second line treatments are essentially palliative.

Hence, the majority of patients suffering from this disease need innovative and novel treatment options, as most patients will ultimately die of their disease with a poor remaining quality of life due to symptoms such as severe shortness of breath and chest pain, due to hardening of the pleura associated with the inevitable disease progression. Innovative approaches such as Kiromics administration of a PD1-GDT CAR, which is designed to address the tumor microenvironment (TME) of MPM are urgently needed.

About Kiromic

Kiromic BioPharma, Inc. is a preclinical stage biopharmaceutical company which is focused on discovering, developing, and commercializing novel immune-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Companys proprietary target discovery engine called "DIAMOND." Kiromic's DIAMOND is big data science meeting target identification, dramatically compressing man-years and billions of drug development dollars to develop a live drug. The Company maintains offices in Houston, Texas.

For more information, please visit the companys website at http://www.kiromic.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

In some cases, you can identify forward-looking statements by terms such as "may," "could," "will," "should," "would," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "project" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading "Risk Factors" included in our Registration Statement on Form S-1 (file no. 333-238153) , originally filed with the Securities and Exchange Commission (SEC) on May 11, 2020, as amended, and elsewhere in this press release. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason. You are advised, however, to review any further disclosures we make on related subjects in our Forms 10-Q, 8-K and other reports filed with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005901/en/

Read this article:

Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA - BioSpace

Trial Court’s Refusal to Reduce Plaintiffs’ Recovery of Costs by Amounts Attributable to Settled Defendants Affirmed – Lexology

Court of Appeal of California, First Appellate District, Division Three, December 11, 2020

The heirs of decedent Richard Booker filed suit, alleging that Booker developed fatal mesothelioma from his exposure to defendants asbestos-containing products. The plaintiffs settled with most of the defendants, and a trial was held against the two remaining defendants, Vanderbilt Minerals LLC and Imerys. The jury found the two defendants liable for increasing the decedents risk of mesothelioma and apportioned 60-percent fault to Vanderbilt and 40-percent fault to Imerys.

The plaintiffs filed a memorandum of costs in the amount of $314,549.54, and Imerys responded with a motion to tax. Imerys sought to reduce the filing fees so that Imerys was only responsible for a one-seventh pro-rata share, and to omit all filing and motion fees related to other defendants. Imerys also sought to tax costs for depositions of corporate representative defendants other than Imerys, for depositions of experts designated by defendants other than Imerys, for the deposition of the plaintiffs expert, and for service of process on the other defendants. Citing Heppler v. J.M. Peters Co., 73 Cal.App.4th 1265 (1999), Imerys argued that when a plaintiff incurs costs associated with its case against numerous defendants, costs may be apportioned amongst the defendants for whom they were incurred.

The trial court partially granted the motion in the amount of $44,948.58. However, regarding Imerys request to apportion costs between it and the other defendants, the court found that it lacked discretion to do so, holding that the Code of Civil Procedure, section 1032, subdivision (a)(4) limits discretionary apportionment of costs to cases where a party recovers non-monetary relief. The trial court concluded that even if Heppler is treated as unique authority for the proposition that a California court can apportion a plaintiffs statutory costs between a judgment debtor and other defendants who prevailed at trial (or, by extension, who settled or were dismissed before trial), Heppler was distinguishable because it involved a construction defect action alleging several entirely distinct defects which made it unfair to burden one defendant, against whom the case was evidently simple, with extensive costs incurred to litigate the unrelated issues. Conversely, in the matter at hand, the plaintiffs claims were based on a single injury to which all defendants conduct alleged contributed in the same general way (asbestos exposure). Therefore, the trial court held that Heppler did not apply and declined Imerys request to tax costs related to other defendants. Imerys appealed this decision.

The right to recover costs under California law is governed by statute, and except as provided by statute, a prevailing party is entitled to recover costs in any action or proceeding (internal citations omitted). Pursuant to California statute Section 1033.5, allowable costs are those that are reasonably necessary to the conduct of the litigation rather than merely convenient or beneficial to its preparation. The determination of whether a cost item was reasonably necessary is a question of fact for the trial court and is reviewed for abuse of discretion. The dispute here centers on whether the trial court had discretion to apportion costs among the original seven defendants named in the case in order to reduce plaintiffs total recovery by the amounts attributable to the defendants other than Imerys,

The court of appeals examined Smock v. State of California, (2006) 138 Cal.App.4th 883, 889, where it rejected a similar request to apportion costs between two co-defendants. Ultimately, the court rejected Imerys argument that the weight of authorities supports its position that trial courts have discretionary authority in all cases to reduce costs against a defendant based on amounts apportionable to other defendants that are no longer in the case. The court found the cases cited by Imerys to be distinguishable, as they all involved situations where some but not all of the parties on the same side of the litigation prevailed against the party seeking costs.

The trial court declined to apportion costs after assuming arguendo that it had discretion to apportion under Section 1032, and the court of appeals found that Imerys failed to demonstrate that the court abused its discretion in doing so, as the courts refusal to tax costs related to other defendants did not exceed the bounds of reason. Ultimately, the court held that the trial court did not abuse its discretion in refusing to reduce plaintiffs recovery of costs by amounts attributable to the other defendants for filing, motions, corporate and expert depositions, and service of process, as such costs were reasonably necessary to the conduct of the litigation and not merely convenient or beneficial.

Link:

Trial Court's Refusal to Reduce Plaintiffs' Recovery of Costs by Amounts Attributable to Settled Defendants Affirmed - Lexology

Nanostructure of the Anodic and Nanomaterials Sol-Gel Based Materials Application: Advances in Surface Engineering – Products Finishing Magazine

by

Xavier Albort Ventura*

Laboratory Electrochemical R&D, Barcelona, Spain

University Politecnic of Catalonia, Barcelona, Spain

Tecnocrom Industrial Cabrera de Mar, Barcelona, Spain

Editors Note: A printable pdf of this paper can be accessed and printed HERE.

ABSTRACT

Numerous metals are processed by anodic oxidation. As a result, one can obtain amorphous barrier-type oxides, crystalline barrier-type oxides or amorphous nanoporous oxides. Currently, highly-ordered nanoporous anodic aluminum oxides (AAO) are obtained with various electrolytes to form nanostructures with a range of geometrical features. This material can serve as a template for nanofabrication of variety of nanowires, nanotubes and nanodots. In this way, porous alumina can be fabricated electrochemically through anodic oxidation of aluminum, yielding highly ordered arrays of nano-holes several hundreds down to several tens of nanometers in size.

Sol-gel chemistry offers a flexible approach to obtain a diverse range of materials. It allows differing chemistries to be achieved as well as the ability to produce a wide range of nano-/micro-structures.

In bio-medical applications, sol-gel materials have been found to hold significant potential. One interesting application relates to hybrid materials that utilize sol-gel chemistry to achieve unusual composite properties. Another intriguing feature of sol-gels is the unusual morphologies that are achievable at the micro, and nano-scale. The ability to control pore chemistry at a number of different scales and geometries has proven to be a fruitful area of study, providing excellent bioactivity, and producing cellular responses and enabling the entrapment of biologically active molecules and their controllable release for therapeutic action.

Key words: Nanostructures, porous alumina AAO membranes, nanoporous anodic alumina (NAA), nanofabrication, sol-gel chemistry, nanocarriers, biomolecules.

1. Introduction

Porous alumina films formed by anodic oxidation of aluminum have been extensively studied for use as molds to form nanostructured materials. The technology of porous alumina and its usage as an anodic oxide coating in tools has a long history.

There is a great demand for the use of highly ordered nano-hole arrays, which can be produced on a scale of several tens of nanometers through self-organization, in a diversity of applications. These include high density storage media, functional nanomaterials exhibiting a quantum size effect, highly sensitive chemical sensors, nano-electronic devices and functional bio-chemical membranes.

Porous alumina membranes of anodic aluminum oxide (AAO) are widely used for the fabrication of various nanostructures and nano-devices. Over the last decade, many materials including nanowires, nanotubes and nanodot arrays, have been fabricated by the deposition of various metals, semiconductors, oxides and polymers inside the pores of AAO membranes (Fig. 1).

Figure 1 - SEM micrographs of an alumina nano-hole array formed by two-step anodic oxidation at 40 V using 0.15M oxalic acid: (a) plan-view, (b) cross-sectional view (Shingubara, et al., 1997).

Nanoporous substrates such as porous silicon, nano-porous anodic alumina, titania nanotube arrays and track-etched porous polymer membranes have been commonly employed as substrates for advanced sensing devices. Nanoporous anodic alumina (NAA) processes produce unique structural, chemical, optical, thermal and mechanical properties and biocompatibility in addition to controllable geometry and exploitable surface chemistries.

Ordered AAO stands out due to its remarkable properties such as chemical, thermal stability, hardness and high surface area. Over the past decade, we have witnessed the emergence of various applications based on AAO membranes such as molecular separation, chemical-biological sensing devices, cell adhesion, catalysis, energy storage and drug delivery vehicles (Fig. 2).

Figure 2 - Schematic diagram showing the typical AAO structureand the major applications for this nanostructured material.

Recent advances in fabrication procedures toward structural modifications and the generation of AAO structures with complex pore geometries, including branched, multilayered, modulated and hierarchically complex pores architectures are presented in Section 2.

Silica and doped silica materials obtained via solution gelation, or sol-gel, inorganic polymerization processes are also highly functional materials with an impressive range of applications, and utilize two of the pillars of chemistry: synthesis and analysis. Simple silica microspheres have since seen numerous applications, and today, the benefits provided by solution gelation are well recognized. In addition, advanced processing routes have also been developed that account for the problematic aspects of the gelation process.

Section 3 aims to describe the sol-gel synthesis routes that are most commonly used to produce ceramic and glass networks for biomedical applications. Sol-gel chemistry offers a flexible approach to obtaining a diverse range of materials. It allows different chemistries to be achieved and offers the ability to produce a wide range of nano-/micro-structures. In addition to providing an overview of the polymerization processes, the use of classical inorganic synthesis routes and colloidal aggregation will be discussed along with adaptations to the synthesis procedures that have allowed for further applications. Common links between methodologies are emphasized and the techniques themselves are discussed through recent applications.

Following this is a more detailed description of the biomedical areas where sol-gel materials have been explored and found to hold significant potential. One of the interesting fields that has been developed recently relates to hybrid materials that utilize sol-gel chemistry to achieve unusual composite properties. Another intriguing feature of sol-gels is the unusual morphologies that are achievable at the micro- and nano-scales.

2. Nanofabrication using a porous alumina template

Self-organized porous alumina nano-hole arrays have been used to fabricate a variety of nanomaterials. These methods are categorized as follows: etching of the semiconductor substrate using a porous alumina film as a mask, pattern transfer using porous alumina as a template for deposition of functional materials in the form of porous alumina nano-hole arrays by electroplating and sol-gel, and deposition of functional materials by chemical vapor deposition (CVD).

a. Porous alumina as an etching mask

The transfer of nano-holes to a semiconductor substrate is promising for applications such as photonic band materials, field emitter arrays and quantum dot arrays. Referring back to Fig. 1, a thin porous alumina film was used as a dry etching mask, by placing it in contact with the substrate. The porous alumina film was delaminated from the aluminum plate by a negative voltage pulse or dissolution of aluminum by dipping in HgCl2 solution. After removal of the nano-hole bottom barrier layer by argon plasma etching or ion beam etching, the porous alumina film was placed on the substrate.

Highly directional ion beam etching is necessary for substrate etching, since the alumina nano-hole aspect ratio (the ratio of depth to diameter ) is very high. The alumina mask showed high tolerance to Reactive Ion Beam Etching (RIBE) using a Br2/N2 mixed gas system (Shingubara, J. Nanoparticle Research, 5, 17-30 (2003)). In this method, maintaining the gap between the porous alumina and the substrate at a mnimum is essential for achieving ultrahigh uniformity.

Recently, an alternative method, using a porous alumina film deposited directly on the semiconductor substrate, was proposed by Shingubara (2003). A thin porous alumina film with an aspect ratio below 5 was formed on a Si/SiO2 substrate by the use of sputtered aluminum. Reactive ion etching using chlorine with a high self-bias of RF plasma proved effective for pattern transfer to Si. There was a significant reduction in hole size due to redeposition of nonvolatile materials on the side wall of the nano-holes. For instance, the initial porous alumina hole size of 40 nm was reduced to 10 nm Si holes when a higher aspect ratio of porous alumina nanoholes in the mask was used. The problem with this method was the non-uniformity of the porous alumina mask thickness, which would require a specially designed anodic oxidation electrode to improve the result.

b. CVD deposition on porous alumina

Chemical vapor deposition of materials in porous alumina nano-holes is a challenging topic for CVD research. Since porous alumina can contain extremely high aspect ratio holes, it is of great interest to discover how high aspect ratio holes can be filled by CVD. Working in a supercritical fluid medium is one way to obtain excellent disposition profiles.

Radium films were synthesized at controlled depths within porous alumina disks by the hydrogen reduction of organoradium compounds dissolved in supercritical CO2 at 50C. Guided by a simple mass transport model, radium films ranging from 1 to 60 microns in thickness were deposited at prescribed depths between 60 and 500 microns.

The formation of carbon nanotubes (CNT) in porous alumina by CVD has been intensively studied. It is well known that CNT-CVD needs catalysis for thermal decomposition. A well ordered array, using electrodeposited Co and Nb located beneath the aluminum layer is shown in the SEM micrograph of Fig. 3.

Figure 3 - SEM image of an array of carbon nano-tubes fabricated in a porous alumina template (Li,et al., 1999).

In the example shown in Fig. 3, using cobalt catalysis, pyrolysis of C2H2 was carried out at 600C. Carbon nanotubes with diameters ranging from 10 to several hundred nanometers and lengths of up to 100 microns can be produced. This structure is highly promising for an ultrahigh-density field emitter array. CNT formed through Co catalysis by this method has a multi-walled structure. Low temperature deposition of CNT at around 500C by microwave plasma-assisted CVD has also been reported.

c. Electroplating on porous alumina

Numerous studies have been conducted on the filling of conductive materials in porous alumina nano-holes by electroplating. Prior to electroplating, the bottom barrier layer should be thinned to less than about 15 nm. Wet chemical etching of the anodic alumina film using dilute chromic acid solution (pore widening treatment), or step-wise lowering of the anodic voltage to 15 V have been employed. Alternating current (AC) or pulsed current electroplating has been used since the impedance of the barrier layer at the nano-hole bottom is too large to allow for direct current (DC) electroplating. Research activity on electroplating magnetic materials in porous alumina has intensified remarkably in recent years. As for other metals, nanowire array formation of gold and silver have been reported.

3. Solgel synthesis on porous alumina

Sol-gel provides an alternative synthesis route for nanomaterial fillings in porous alumina nano-holes.

Monodispersed hollow nanocylinders containing crystalline titania particles have been filled by an aqueous solution of titanium tetrafluoride.

Hollow nanotubes comprised of In2O3 and Ga2O3, have been synthesized by sol-gel chemistry and sol-gel synthesis of an array of C-70 single cristal nanowires in a porous alumina template.

a. Organic precursors in sol-gel methods

Silicon alkoxides represent the main network forming agents used in sol-gel preparation methods. While the sol-gel process provides key benefits, such as the low synthesis temperatures and the vast array of alkoxide precursors available, the cost associated with alkoxide precursors presents some limitations.

Nevertheless,the efficiency provided by low temperature synthesis and the accuracy with which specific compositions can be achieved have the potential to outweigh any such negative aspects of the process. Low temperature synthesis is achieved through solution-mediated formation of strong covalent bonds between elements that would otherwise require excessively high temperatures to create. For alkoxides this requires initial hydrolysis of the alkoxy group followed by as condensation between network forming substrates (Fig. 4).

Figure 4 - Initial hydrolysis and condensation stages of tetraethyl orthosilicate - Si(OC2H5)4 (TEOS) in the production of silica oligomers: (a) Introduction of water to TEOS, (b) H2O forms a hypervalent substrate with silicon, (c) transfer of the proton from the water to the adjacent alkoxy group, (d) cleavage of the ester bond and dealcoholation.

Sol-gel methods also enable the powderless processing of glasses, ceramics and thin films or fibers directly from solution. Precursors are mixed at the molecular level and variously shaped materials may be formed at much lower temperatures than is possible by traditional preparation methods.

One of the major advantages of sol-gel processing is the possibility of synthesizing hybrid organic-inorganic materials. Combinations of inorganic and organic networks facilitate the design of new engineering materials with diverse properties for a wide range of applications. Biomedical applications invariably require the design of new biomaterials, and this can be achieved by emerging sol-gel chemistry and biochemistry. The gel-derived materials are excellent model systems for studying and controlling biochemical interactions within constrained matrices with enhanced bioactivity because of their surface chemistry, micro-/nano-pores and large specific surface area. In biomedical applications, the coating of medical devices is an important issue. Materials used in medical devices should have appropriate structural and mechanical properties and ideally promote a healing response without causing adverse immune reactions. Medical services designers currently use various surface treatments such as coatings that enhance or modify properties such as lubricity, the degree of hydrophobicity, functionalisation and biocompatibility. Sol-gel technology offers an alternative technique for producing bioactive surfaces for these applications.

Sol-gel thin film processing offers a number of advantages including low-temperature processing, ease of fabrication, and precise microstructural and chemical control. The sol-gel derived film or layer not only provides a good degree of biocompatibility, but also a high specific surface area and an external surface whose rich chemistry allows ease of functionalization by suitable biomolecules.

The development of multifunctional nanoparticles that can be used as drug delivery vectors remains a significant challenge of material science. These applications require intimate control of the particle size and discrete, superparamagnetic iron oxide nanoparticles that can be prepared by the sol-gel method to lower the annealing temperatures required.

Silica-based magnetic nanocomposites, formed by magnetic nanoparticles (MNP) dispersed in a silica matrix, are of relevant technological and scientific interest. Here encapsulation in silica prevents interactions between the MNPs, and consequently assures a uniform dispersion. The latter is essential for efficient performance in most applications, including the diagnostic and therapeutic areas, where particles must display high magnetization, be stable against oxidation and most importantly, remain nonaggregated.

Engineering new bone tissue with cells and a synthetic extracellular matrix (ECM) represents a promising approach for the regeneration of mineralized tissues. Bone regeneration requires a scaffold material upon which cells can attach proliferate and differentiate into functionally and structurally appropriate tissues for the body location into which they are placed .

Bone is a highly mineralized tissue consisting of an apatitic mineral phase most similar to a form of carbonated hydroxyapatite (HCA), although a significant contribution is made by extraneous ions such as sodium chloride, zinc and, to a lesser extent, fluorides. In general, HCA can be considered a model mineral for natural bone and is widely accepted as a bioactive material with excellent biocompatibility, high osteoconductivity, and reasonable mechanical strength. For these reasons, it has been widely used in tissue engineering applications, especially for bone and cartilage regeneration.

However, in vivo data suggest that degradation or ion release from labile sources such as bioactive glasses promotes new bone formation, as opposed to the relatively lower ion release that occurs as a result of HCA minerals reaching equilibrium with their surrounding medium. It appears that sol-gel methods hold the potential to apply an ever-increasing range of glass-based bioactive coating to materials, which have previously remained incompatible with alternative coating techniques. Furthermore, the versatility of the sol-gel approach is opening new doors to previously unattainable compositions, again increasing the potential applications of sol-gel materials as fillers to replace tissue within necrotic or defect sites.

Sol-gel microencapsulation technology and its broad application potential are now well-known. Relevant here is the use of silica for encapsulation and controlled release of both hydrofilic and hydrophobic molecules, ensuring considerable chemical and physical protection of the valued entrapped dopants. Given the above, it can be seen that sol-gel derived bioactive materials hold great potential value.

b. Sol-gel methods and reactions processes

The sol is a colloidal suspension of solid particles, whereas a gel is an interconnected network of solid-phase particles that form a continuous entity throughout a secondary, usually liquid phase. Throughout sol-gel technology, these phases are conserved though the chemical reactions that take place during the gel evolutions, and can be manipulated in a variety of ways, e.g., altering the initial precursors, time allowed for gelation, catalysts, degree of solvation, gelation conditions or physical processing of the gel itself. Sol-gel processes allow the formation of solid materials through gelation of solutions and can be used to produce a large number of useful morphologies. The processes are illustrated in Fig. 5.

Figure 5 - Sol-gel synthesis routes: Processes are defined as sol-gel by the transition of a colloidal solution to an interconnected gel network (gelation). The further processing stages illustrated are non-redundant and may be combined depending on the specific needs of the application.

What remains constant for the production of sol-gel derived bioactive materials are the stages that allow for hydrolysis and condensation reactions to occur. Successful manipulations of these reactions are shown in Fig. 6.

Figure 6 - Subsequent condensation stages of TEOS in the production of silica oligomers. Condensation between silanol groups on two hydrolyzed TEOS molecules (a and b) and between a silanol group and an adjacent alkoxy group (c and d) result in the production of free H2O and ethanol respectively.

Figure 6 shows that only one reaction occurs during condensation: the loss of an HO-group from the substrate. This mechanism is therefore a reaction that can occur as either dehydration or dealcoholation. For the former to occur, two HO-groups must take part in the formation of an Si-O-Si bond, whereas the latter results from the direct transfer of a proton to the leaving group on a neighboring substrate.

As evident from these reactions, a decrease in pH can promote hydrolysis through protonation of the leaving groups. Alternatively, higher pH will induce the deprotonation of OH- groups and therefore favor condensation. However, OH- is a highly efficient nucleophilic species and electron transfer from -OH groups can be facilitated by H+ in the immediate environment. This relationship means that higher and lower pH values are also able to promote condensation and hydrolysis, respectively. In silica-based systems, the reactions proceed by acidic catalysis at pH < 2.5 and basic catalysis when pH < 2.5 ,which can be explained by the isoelectric point of silica at pH 2.5.

In the sol-gel route synthesis, a stepwise reaction scheme has been undertaken to control the ratio of hydrolysis to condensation rates. In general, the rate of hydrolysis is fast compared to that of condensation in strong acidic conditions. Therefore, a well-ordered hexagonal arrangement of mesopores (a pore structure that is commonly formed in sol-gel silica materials) is formed at low pH in acidic conditions. Meanwhile, in neutral or basic conditions ranging from pH 7 to pH 9, the rate of condensation is faster than that of hydrolysis, and eventually the materials prepared by a single-step reaction at high pH display a gel-like structure often without mesopores. However, the higher electronegativity of transition metal species as compared to silicon and phosphorus can cause issues where condensation reactions proceed with an unfavorable bias away from the desired network composition or the end particulate structure.

Like silicon, phosphorus and vanadium precursors can be used as network-formers within the sol-gel process. This difference in network connectivity results in a more relaxed network structure when compared to silica-based networks, as silicate is able to share all four oxygen atoms with neighboring cationic groups. This in turn increases the range and quantity of species that are able to be included, but such flexibility comes at the expense of stability, as the high electronegativity of the =O bond leaves the network open to hydrolysis. As with conventional melt-derived materials, solubility can be controlled by the combination of network modifiers, as can the release of active agents or tailoring of other physical properties of the material in question.

The solvent itself also plays an important role in determining the rate of gelation reactions. This solvation effect can occur in two ways: through viscosity or hydration effects. However, the solvent is shown to alter the NiO2 crystalline structure, which serves to highlight the need for experimental confirmation as, with such a variety of avenues available to exploit, comes as set of variables that must also be controlled, including the effects of viscosity, or more precisely the dielectric constant.

By altering the solvent species from that of the alkoxide itself, the substrate can become coordinated with a mixture of alkoxy groups. Undoubtedly, this would affect polymerization in a way that is dependent on a specific combination of coordinated groups present on network-forming substrates throughout the solution.

The initial Si-O-Si bridges that are formed can be further strengthened by passive deposition of silica on the initial bridge as a result of the equilibrium orthosilicic acid Si(OH)4, and the silica making up the mass of the colloids. Furthermore, colloidal sol-gel methods are not limited to silica or silica-based systems.

The applicability of the colloidal methods is based on two key aspects of the process stabilization of the colloidal particles within the sol and coalescence or flocculation to form the gel. With particles that possess the same electrostatic charge, colloidal suspensions are maintained by the potential, which in turn reflects the magnitude of the electrical double layer present on charged particles in solution. As noted above, the removal of the solvent is one method by which the aggegation of colloidal particles can be achieved. Alternatively, altering the pH, salinity or temperature can induce depeptization, whereby the electrical double layer is reduced to a point where the potential is no longer strong enough to prevent attractive Van der Waals forces and flocculation takes place.

Despite the potential of colloidal methods to provide much thicker, more structurally resistant films and deposits than methods that rely on de novo synthesis,** this route has seen the least number of applications within biomedical research. The gelation rate correlates well with the structural stability of the encapsulated proteins and serves to demonstrate an ability to circumvent conditions that would otherwise damage sensitive molecules. For certain applications however, the colloidal sol-gel method does not provide the degree of protection required.

Colloidal methods offer a further benefit over alkoxide based systems in that the majority of the network is already present in the sol. Adaptations such as the introduction of osmoprotectants can therefore be applied without significantly interfering with the integrity of inorganic capsule itself.

c. Metal chelation in the sol-gel

In aqueous solution, metal ions are coordinated by a hydration shell, the nature of which depends both on the valence of the specific metal in question and the pH of the solution. This ultimately results in the formation of polymeric oxides in solution.

The hydroxy-ligand thus formed is able to act as a bridge between the two hydrated metal complexes. This results in the release of a proton into the aqueous medium and is followed by a subsequent deprotonation event resulting in a M-O-M covalent bond. From this brief description alone, the influence of pH on the process can also be deduced. An increase in pH favoring olation and the lower pH inhibiting the process.

Undoubtedly, materials composed of metal oxides exhibit a wide range of desirable properties and as a result, a series of methods have been developed based on chelation of metal precursors in order to control the natural polymerization processes. Essentially, metal chelation sol-gel methods employ strong chelating agents (such as citric acid or EDTA) as a means of controlling the formation of the highly reactive hydrated complexes.

Although discussed here in terms of chelated inorganic precursors, chelation itself is not limited to inorganic processes. Such methods can also be applied to modify the polycondensation of metal alkoxides whereby the rate of reaction is reduced following the replacement of alkoxide, leaving groups with a chelating ligand in more stable conformation.

In further discerning metal chelation methods from the alkoxide sol-gel route, the underlying principle is that polycondensation of the metal itself occurs through hydration processes described above, as opposed to the hydrolysis and condensation steps akin to the polymerization of organometallic precursors.

Based on a system that made use of triethanolamine as an Fe(II) chelating agent, triethanolamine is able to form chelation complexes with a wide range of transition metal elements, therefore offering a plausible route for further biologically relevant substitutions within the network.

The use of epoxides as gelation agents provides another useful synthesis pathway. Typically, epoxide routes are most effective when the formal oxidation state of the dopant cation is M+3, although species that possess a lower valence may also be incorporated. In this instance, the epoxide does not act as a precursor per se. Rather, the epoxide group is able to efficiently accept protons, leading to the formation of hydrated oxo-ligands M(H2O)n(O)m-n)+2 coordination until deprotonation in the presence of an epoxide.

Although not strictly a chelation-base methods parallels can be observed between this approach and the more typical chelation methods that aim to prevent natural polymerization processes until required.

d. Polymer assisted sol-gel

In a natural extension from metal chelates methods are the polymeric sol-gel methods. Essentially these methods involved the chelation of reactive inorganic gel-forming agents within an organic polymer network although, depending on the material to be produced, chelation is secondary to stabilization. In broader terms, gel forming agents are maintained within in a state of dispersion throughout the solution, thereby preventing the precipitation of aggregates within the sol. This method does however require subsequent heat treatment to remove the organic polymer following the formation of the inorganic gel.

Chemical properties,such as the biomimetic*** molar ratios of apatites, can also be achieved with polymer assisted stabilization due to the homogeneous elemental distribution of the gel network.

Inorganic networks can also be formed in situ through the polymerization of organic precursors. This method involves the formation of a three-dimensional polyester network resulting from the reaction between ethylene glycol and citric acid. The citric acid acts as a chelation agent due to an available bi-dentate binding mechanism followed by an esterification with ethylene glycol (Fig. 7). The organic network would be removed as with ex situ polymers as described above.

Figure 7 - Esterification (condensation) of ethylene glycol and citrate in the presence of a cationic ligand (calcium).

Effective production of both biocompatible ceramic-mineral composites and apatites with predefined stoichiometry has been achieved, with polymer-assisted sol-gel methods. Such research may also have broader implications than in solving issues associated with biocompatibility as, with the advent of controlled deposition of inorganic mineral layers, a biotic hard tissue regeneration may also be within reach.

e. Silica-based sol-gel materials

Silica-based sol-gel materials have been the subject of intense interest for the last three decades. Biomolecular encapsulation within sol-gel-derived silica matrices was first successfully achieved by entrapping enzymes into TEOS matrices.

During the last few decades, silica-based materials have supplied successful solutions for soft and hard tissue regeneration. These materials are highly biocompatible and the positive biological effects of their reaction products make them an interesting group of materials for tissue regeneration. Silica-based bio-reactive glasses were first synthesized via a sol-gel technique at lower processing temperatures compared to the melt derived glasses. Extensively researched sol-gel glasses were based on the SiO2-ONa-P2O3 system for biomedical apllications. Silica-based sol-gel glasses exhibit many of the properties associated with an ideal material for tissue regeneration, such as high surface area and a porous structure, in terms of overall porosity and pore size, that promote cell-material interactions and cell invasion. Research on these glasses showed that their porous structure exhibits a higher surface area that exhibits higher tissue bonding rates.

A sol-gel process, involving the foaming of a sol with the aid of a surfactant, followed by condensation and gelation reactions, has been used to prepare porous scaffolds of a few bioglasses, such as the glass designated with the composition (mol%): 40 SiO2-2O-ONa-2P2O3. The as-prepared scaffold had an overall microstructure similar to that of dry human trabecular bone, but the pore structure was hierarchical consisting of interconnected macropores <90 microns, resulting from the forming process and mesopores that are inherent to the sol-gel process.

Figure 8 - Plan-view SEM micrographs of porous alumina film surfaces that were formed by AFM nano-indentation, followed by anodic oxidation at 40 V using 0.15M oxalic acid for 5 min. Indentation force was 4.16105 N. The indentation interval was varied from 55 to 110 nm. (Shingubara, et al., 2002).

Figure 8 illustrates the porous structure of the scaffolds made of bio-active glasses produced by means of the sol-gel processes. This hierarchical pore structure of the scaffolds is beneficial for stimulating interaction with cells as it mimics the hierarchical structure of many natural tissues and more closely simulates the physiological environment of mineralized tissues. Thanks to the nanopores in the glass, sol-gel derived scaffolds have a very high surface area (100-150 m2/g). As a result, these scaffolds degrade and convert faster to via a hard anodizing process than those of melt-derived glass with the same composition. However, these sol-gel-derived scaffolds have a relatively low compressive strength, and consequently, they are primarily suitable for applications focused on low load bearing orthopedic sites.

Go here to read the rest:

Nanostructure of the Anodic and Nanomaterials Sol-Gel Based Materials Application: Advances in Surface Engineering - Products Finishing Magazine

Evelyn Hu delivers 2020 Dresselhaus Lecture on leveraging defects at the nanoscale – MIT News

Harvard University Professor Evelyn Hu opened the 2020 Mildred S. Dresselhaus Lecture with a question: In an imperfect world, is perfection a necessary precursor for transformative advances in science and engineering?

Over the course of the next hour, for a virtual audience of nearly 300, the Tarr-Coyne Professor of Applied Physics and Electrical Engineering at the John A. Paulson School of Engineering and Applied Sciences at Harvard University argued that, at the nanoscale, there must be more creative ways to approach materials. By looking at what nature gives us in terms of electron energy levels, phonons, and a variety of processes, Hu said, scientists can re-engineer the properties of materials.

To illustrate her point, Hu described the effect of defects vacancies or missing atoms in otherwise perfect crystalline semiconductors. In transforming these defects, Hu demonstrated how unique properties at the nanoscale involving quantum confinement can profoundly change electron density of states. Hus talk exemplified the exceptional scholarship and leadership that have defined her career, says Vladimir Bulovi, the founding faculty director of MIT.nano.

Professor Hu has developed groundbreaking techniques for designing at the nanoscale, used those techniques to produce extraordinary innovations, and extended her impact through inspirational mentorship and teaching, says Bulovi, who is also the Fariborz Maseeh Professor of Emerging Technologies. We were honored to have her present this years Dresselhaus Lecture."

Hu attended the same high school as Dresselhaus Hunter College High School in New York City a coincidence that was like a good luck talisman to me, she said. It gives me such great pleasure to try and express my gratefulness to Millie for all the guidance and mentorship shes given to me from the time I was a graduate student and the inspiration that she's given to us all.

2020 Mildred S. Dresselhaus Lecture: Evelyn Hu, Harvard University

Making a perfect material less perfect

Inspired by Dresselhauss work in the early 1990s to rethink thermoelectric materials, Hus research group is working on new ways to engineer materials that can exhibit a combination of photon correlation and spin coherence. Her talk showcased how silicon vacancies in silicon carbide, when integrated within nanoscale optical cavities, can result in a controlled output of light. The integrated defect-cavity system can also serve as a nanoscope into the material, allowing scientists to learn about the interactions with surrounding defects, providing broader insights into long-term quantum coherence.

Hu displayed an image of a perfect, single crystal semiconductor, then quickly disrupted that perfection by removing the silicon atoms to create a silicon vacancy. Changing the material in this way allows her to look for opportunities, she said. Think of vacancies not as something missing, Hu explained, but as atom-like entities with particular electronic and spin states embedded in a complex, wide bandgap environment. The silicon vacancy has ground and electronic states. It also has an electron spin.

In order to obtain enough signal from this single atomic scale defect, Hu manipulates the nanoscale to create an integrated environment for the silicon vacancies that she calls a cavity. Think of this as a breakout room, she says. A place our atomic-scale silicon vacancy can be in an intimate and isolated conversation with its environment.

The cavity recycles the photon energy as it goes back and forth between the emitter and this environment. When the silicon vacancy is placed within this cavity, the signal-to-noise is enormously better, Hu said.

At the end of her lecture, Hu answered audience questions ranging from scalability of her work and mathematical models that enumerate these discoveries, to limiting factors and the use of molecules as active spin states as compared to crystalline semiconductors. Hu concluded her talk by reflecting on Dresselhauss legacy, not only as a great scientist but as someone who was beloved.

This word, she says, means a degree of trust, of willingness to follow, to believe, to listen to. For a scientist and engineer to be beloved in that way, and to have trust in that way, makes the difference between effectiveness and the ability to affect change.

Honoring Mildred S. Dresselhaus

Hu was the second speaker to deliver the Dresselhaus Lecture. Established in 2019 to honor the late MIT physics and electrical engineering professor Mildred Dresselhaus, the Queen of Carbon Science, the annual event features a speaker selected by a committee of MIT faculty from a list of nominations submitted by the MIT community, scholars from other institutions and research laboratories, and members of the general public. The process and lecture are coordinated by MIT.nano, an open access facility for nanoscience and nanoengineering of which Dresselhaus was a strong faculty supporter.

Muriel Mdard, the Cecil H. Green Professor in MITs Department of Electrical Engineering and Computer Science, opened the lecture with an invitation to nominate candidates for a new honor named for Dresselhaus by the Institute of Electrical and Electronics Engineers (IEEE). Established in 2019, the IEEE Mildred Dresselhaus Medal will honor an individual for outstanding technical contributions in science and engineering of great impact to IEEE fields of interest. Were really looking for people who have had an impact that goes beyond the technical, says Mdard. Do consider nominating a worthy colleague, somebody whom you feel reflects well the kind of qualities that made Millie so remarkable.

Nominations for the 2021 Dresselhaus Lecture are broadly accepted and can be submitted on MIT.nanos website at any time. Any significant figure in science and engineering from anywhere in the world may be nominated.

Original post:

Evelyn Hu delivers 2020 Dresselhaus Lecture on leveraging defects at the nanoscale - MIT News

COVID-19 airborne transmission research suggests potential therapies | University of Hawaii System News – UH System Current News

A new University of Hawaii at Mnoa College of Engineering review article presents a breakthrough in multidisciplinary understanding of the airborne transmission of COVID-19 and researchers say they hope the findings will contribute to future public health guidance.

There have been more than 70 million confirmed COVID-19 cases worldwide. However, despite the urgency of the pandemic, the physical modes of COVID-19 transmission are still poorly understood. In particular, transmission by aerosols has recently come under focus. Aerosols are microscopic airborne particles that, due to their small size, can remain suspended in air for a long time, instead of falling directly to the ground.

An integrated review published in ACS Nano by mechanical engineering Professor Yi Zuo and Assistant Professor William Uspal, together with Associate Professor Tao Wei from Howard University, covers the entire exhalation-to-infection pathway. Drawing on aerodynamics, thermodynamics, molecular biophysics and other fields, their review considers how infectious aerosols disperse in the air, deposit in the lung and interact with cell receptors.

During our review of the previous research, we found that a lot of cutting-edge research has not yet been integrated into public health guidelines in understanding COVID-19 transmission, Zuo said. Furthermore, we realized just how much engineering perspectives still have to contribute to the effort against the pandemic.

The team believes that its review may stimulate the development of mitigation approaches, such as ventilation protocols, and new therapeutic interventions, such as surfactant therapy to alleviate COVID-19-induced acute respiratory distress syndrome. Surfactants are substances that, when added to water, reduce surface tension. In several ongoing clinical trials worldwide, natural surfactants extracted from animals lungs have been given to ventilated COVID-19 patients as a supportive therapy to ease breathing, and provide more time for other therapeutic interventions.

According to Uspal, the most urgent message is, Wear masks. Masks are particularly effective for large droplets. Ideally, masks worn by infected, but asymptomatic people would filter out most exhaled droplets before they have a chance to shrink by evaporation and become aerosols.

Zuos research is funded by the National Science Foundation, and Uspals research is funded by the American Chemical Society Petroleum Research Fund.

Read the original here:

COVID-19 airborne transmission research suggests potential therapies | University of Hawaii System News - UH System Current News

Engineers awarded for ongoing research excellence – News – The University of Sydney

Professor Anna Paradowska

Professor Anna Paradowska has been named recipient of the Australian Neutron Beam Users Group (ANBUG) Neutron Award for her outstanding research in neutron science and leadership promoting the Australian neutron scattering community.

Professor Paradowska has pioneered industrial engagement at Australias Nuclear Science and Technology Organisations (ANSTO) Australian Centre for Neutron Scattering (ACNS), utilising neutron scattering techniques to solve industry problems with particular focus on advanced manufacturing.

Over the years, Professor Paradowska has developed successful collaborations with Australian and global industry as well as universities in the area of advanced and additive manufacturing.

The primary goal of her research is to relate residual-stresses, mechanical and metallurgical properties to manufacturing procedures and integrity requirements of engineering components.

I am delighted with this peer recognition as it is a fantastic feelingto know that my research contributions are being seen and appreciatedby the community, said Professor Paradowska, a co-appointed Professor Practice between the School of Civil Engineering and ANSTO.

Neutron scattering has an enormouspotential to help solve range of industry problems, and the full potential of those various method is yet to be discovered by the industry.

The award is the latest achievement for the international expert in neutron diffraction stress analysis, having previously been named recipient of the ASM Henry Marion Howe Medal for co-authoring materials paperIn Situ Study of the Stress Relaxation During Aging of Nickel-Base Superalloy Forgings.

The ASM Henry Marion Howe Medal is a prestigious prize intended to honour the author(s) whose paper has been selected as the best of those published in a specific volume ofMetallurgical and Materials Transactions.

As part of the project, Paradowska measured residual stresses in the superalloys duringin situheat treatmentson theKowari strain scannerand the same procedure was repeated at other neutron facilities.

The results demonstrated that thenewly-developed induction heating setup could be repeated successfullyon several instruments across three continents and reassure the scientific and industrial community that residual stress relaxation can be measured accurately and systematically.

Furthermore, Professor Jun Huang and Professor Marcela Bilek, who are also members of the University of Sydney Nano Institute have also been honoured for their engineering work.

Visit link:

Engineers awarded for ongoing research excellence - News - The University of Sydney

New Horizons for research through new adventurous research projects – The University of Manchester

Dr Golovanov, who leads this research, said: The ability to deliver significant amount of light, at any wavelength, within extremely constrained geometry of the NMR instruments allows us to look in real time at any phototransformations as they happen in front of our eyes in the NMR tube. It can be anything photoreactions, photoenzymes, photo-controlled conformational switches or nano-machines anything.

New Horizons forms part of UKRIs wider Reforming our Business agenda to simplify and streamline processes and practice across the organisation.

Elsewhere at The University of Manchester, Professor Catherine Powell intends to develop new algorithms for forward uncertainty quantification, which allows us to understand how uncertain inputs in mathematical models affects predictions of outcomes of interest. This could have a transformative effect on a wide range of engineering applications involving physics-based models.

EPSRCs 2019 Delivery Plan highlighted the desire to continue promoting excellence in research by investing in new approaches to delivery that are optimised to the specific researcher base and research outputs desired.

Science Minister Amanda Solloway said:It is critical we give the UKs best researchers the resources to drive forward their revolutionary ideas so they can focus on identifying solutions to some of the worlds greatest challenges, such as climate change.

This government funding will allow some of our brightest mathematicians and physicists to channel all their creative ingenuity into achieving potentially life-changing scientific breakthroughs from mathematics informing how we save our rainforests to robotics that will help track cancer faster.

EPSRC Executive Chair, Professor Dame Lynn Gladden, said:New Horizons reflects EPSRCs commitment to funding creative, transformative and ambitious new ideas across our portfolio. In this pilot, we have funded more than 100 projects in the mathematical and physical sciences.

The scheme also piloted a new, simplified applications process designed to minimise the administrative burden of submitting grant applications, thereby enabling researchers to focus on developing their research ideas.

The call for proposals attracted a very positive response in terms of both the number and quality of applications and we look forward to exploring how to include the approaches taken through New Horizons in further areas of our portfolio.

Read the original here:

New Horizons for research through new adventurous research projects - The University of Manchester

New collaboration provides opportunity for future water scientists and engineers – Cranfield University

The first cohort of IWA-Cranfield Scholarship winners have commenced their journey to become the next generation of water scientists and engineers.

Awarded scholarships by the International Water Association and Cranfield, the students will develop their technical understanding and business skills to become leaders in the worldwide fight to improve the resilience and sustainability of water supply and sanitation systems and protect the natural environment.

Selected from more than 500 high quality applicants, 14 full-fee scholarships were awarded by the University across three MSc courses: Water & Wastewater Engineering, Advanced Water Management and Water & Sanitation for Development.

Safe water and sanitation for all

Sharriff Irfan Ulla is one of the recipients of the scholarships and is studying on the Advanced Water Management MSc. He said: It is my desire to take the principle of water should be an essential right, not an entity of privilege forward by making safe water and sanitation available at household level and creating independent water management as standard practice. In a developing country like India, managing water is one of the most significant challenges. I believe that a holistic approach to water management practices will ensure quality water availability for future generations.

Increasing the skills base

Professor Paul Jeffrey, Director of the Water theme at Cranfield University, said: These scholarships across our full range of postgraduate programmes will help develop the next generation of leaders that we desperately need in the water industry, both in the UK and around the world.

If we are to realise the UN Sustainable Development Goal of ensuring availability and sustainable management of water and sanitation for all, then we need to increase the skills base of water scientists and engineers, who can help develop the solutions to these global challenges.

Im extremely grateful for the support of the International Water Association in enabling us to provide these scholarships - together, we are both committed to training and nurturing future technical specialists and leaders for the global water sector.

Nasreen Nasar is also one of the recipients of the scholarships. She said: The Cranfield-IWA excellence scholarship provides an ideal platform to foster and equip future scientists and engineers to take on the current and future challenges in the water and wastewater sector. This resonated very well with my career aspiration, which led me to apply for it. By studying the MSc on Water and Wastewater Engineering at Cranfield University while getting involved with the IWA, Im looking to be a part of a dynamic group of scientists and engineers who are at the forefront of redefining the concept and functionality of water and wastewater treatment plants in the context of a circular economy. It is truly an honour to be selected for this highly esteemed scholarship.

Scientists and engineers at Cranfield are involved in a number of projects that are seeking technological solutions to global challenges of inadequate sanitation, reliable water quality for communities and the impacts of flood and drought on farming. The work on the Nano Membrane Toilet, funded by the Bill and Melinda Gates Foundation, is just one example.

You can find out more about the next funded scholarships here.

About the IWA

The International Water Association (IWA) is a network and an international global knowledge hub open to all water professionals and anyone committed to the future of water. With its legacy of over seventy years, it connects water professionals around the world to find solutions to global water challenges as part of a broader sustainability agenda.

As a non-profit organisation and with a membership in more than 140 countries, the IWA connects scientists with professionals and communities so that pioneering research offers sustainable solutions for a water-wise world. In addition, the association promotes and supports technological innovation and best practices through international frameworks and standards. For more information, please visit iwa-network.org.

Cranfield Universityis a specialist postgraduate university that is a global leader for education and transformational research in technology and management.

Read more:

New collaboration provides opportunity for future water scientists and engineers - Cranfield University

First of its kind at U of T: MIE launches specialized course in 3D printing – U of T Engineering News

The Department of Mechanical and Industrial Engineering (MIE) is launching a new course to train students in additive manufacturing, commonly known as 3D printing. Launching in Winter 2021, it is the first course of its kind at U of T.

MIE1724: Additive Manufacturing in Engineering Applications focuses specifically on the rapidly evolving and lucrative field, which generates upwards of $13 billion in yearly revenue and is applicable to numerous sectors.

The course is the creation of alumnus Ali Radhi (MIE PhD 1T9), who wanted to provide a graduate-level specialized class that looks at the process of designing and building cost-effective and timely products using novel materials and hardware.

Radhi spoke to MIEs Kendra Hunter about the new course and preparing todays students for the design and fabrication of complex structures.

What inspired you to create this course?

At MIE, I have been involved in the design of lightweight structures and saw there was room to further bridge the fields of materials and manufacturing through a new course. A recent trend in 3D printing is to produce complex structures using materials with properties not usually found in nature, such as invisibility cloaks, and I wanted to address this while giving singular focus to the field of additive manufacturing, 3D printing and their respective applications. Professor Tobin Filleters MIE 1744: Nanomechanics of Materials provided inspiration in expanding this area of knowledge and from there, MIE1724 took shape.

What can students expect from this course?

The course introduces various types of additive manufacturing approaches, including multi-material 3D printing, micro/nano additive manufacturing and 3D bioprinting. MIE1724 is also designed to show the limitation of selected additive manufacturing methods. Characterization of additive manufacturing parts is included as a major course outcome. Ithelps students to integrate design for additive manufacturing aspects in industry product fabrication.

Students get to learn about new 3D printing technologies, and how they are applied to solve problems in security, automation, and more.

The course will first introduce the concept of 3D printing, and then will move into computer-aided design (CAD) for additive manufacturing. Currently, students can request parts to be 3D printed through the Myhal Centres Fabrication Facility but once it is safe to do, they will be able to receive training to use the facility for their own education and research.

How does this course benefit degree and career options?

3D printing is now the primary method of prototyping. More recently, it became the sole method for end-use part production for highly complex structures and/or material content. Dedicated post-secondary education in 3D printing helps fill the talent gap in additive manufacturing as global revenue from these technologies has jumped from $4 billion to $13 billion from 2014 to 2018.

Additive manufacturing shortens design and production processes by enabling companies to streamline prototyping activities, alter supply chains, and evolve end-product manufacturing. The market is growing at a rapid pace and people with a specialization in additive manufacturing will be in demand.

Did you design MIE1724 strictly as an engineering course for engineering students?

No, in fact this course is open to all U of T students. 3D printing is of great interest to many fields such as medicine, architecture and dentistry. The course is structured to highlight the technologys potential, process and applications in those fields and much more. The course also addresses unique fields, such as textiles and cosmetics, and how this technology can be applied. Additionally, the areas of information science, education and graphic design also benefit with over 250 applications of additive manufacturing that can be incorporated into their daily use of technology.

How did your PhD studies at MIE help you develop the skills to create MIE1724?

The PhD program provided a lot of exposure to state-of-the-art fabrication technologies. 3D printing was one of those avenues, and I took part in design projects and competitions that employed such technologies within the facilities at U of T. Furthermore, the teaching assistant and instructor opportunities from the University helped me to identify the knowledge gap in 3D printing from U of Ts broad list of advanced courses. During my PhD studies, collaboration with fellow research groups aided my own research through sharing of knowledge with my network as well as training in high- tech research facilities.

MIE1724 was inspired by Professor Filleter and Professor Eric Dillers (MIE) research both were helpful and supportive in providing insights for a proper scope and delivery for the course. Associate Chair of Graduate Studies for MIE, Professor Murray Thomson (MIE), provided support to address student expectations and Maximiliano Giuliani, Senior Facility Supervisor at the Myhal Centre for Engineering Innovation and Entrepreneurship, provided input on expected knowledge and training for students before using his facilities for 3D printing.

Read more from the original source:

First of its kind at U of T: MIE launches specialized course in 3D printing - U of T Engineering News